Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD, a type of lung disease, sending the British firm’s stock to its lowest in 21 months.
Flutiform had not significantly reduced the yearly rate of worsening conditions in patients with moderate and severe chronic obstructive pulmonary disease (COPD), versus mono-component LABA treatment, respiratory drug specialist Vectura said on Tuesday.
Source: Reuters
Filed Under: Drug Discovery
